Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Treatment
Doxycycline enhanced tumor regression activity of cyclophosphamide
April 19th, 2005
Researchers suggested that doxycycline (DOX) enhances the tumor regression activity of cyclophosphamide (CPA) when treating breast cancer. "CPA is a widely used chemotherapeutic drug in neoplasias. It is a DNA and protein-alkylating agent that has a broad spectrum of activity against variety of neoplasms including breast cancer. The therapeutic effectiveness of CPA is limited by the high-dose hematopoietic, renal, and cardiac toxicity that accompanies the systemic distribution of liver-derived activated drug metabolites," scientists in India reported. "The present study examines the potential of combining well-tolerated antibiotic DOX with CPA and...
Source: Cancer Weekly (2005-04-19)
|
